Research programme: eye disorder therapeutics - GrayBug

Drug Profile

Research programme: eye disorder therapeutics - GrayBug

Alternative Names: GB-102; Sunitinib maleate depot - GrayBug

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator GrayBug inc.
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

  • 04 May 2016 Pharmacokinetics data from a preclinical study released by Graybug Vision
  • 02 May 2016 Graybug Vision plans a phase I/II trial for Wet age-related macular degeneration in USA
  • 12 Nov 2015 Preclinical trials in Eye disorders in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top